Global Hemophilia Researchers and Caregivers Receive $2.75 Million in Grants from Bayer Biological Products; For three years consecutively, Bayer Hemophilia Awards Program supports research into the next generation of hemophilia care.SYDNEY, Australia -- The Biological Products Division of Bayer HealthCare, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , (Bayer BP) today honored 26 healthcare professionals and caregivers from the worldwide hemophilia hemophilia (hē'məfĭl`ēə,–fēl`yə), genetic disease in which the clotting ability of the blood is impaired and excessive bleeding results. community representing the 2005 Bayer Hemophilia Awards Program (BHAP) grant recipients. Awardees will receive a total of $2.75 million in grants to fund basic and clinical research, as well as educational programs to advance the state of hemophilia care. The award recipients were honored at a special dinner reception held in conjunction with the XXth Congress of the International Society on Thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. and Haemostasis hemostasis, haemostasis the stoppage of bleeding or cessation of the circulation of the blood; stagnation of the blood in a part of the body. Also hemostasia, haemostasia. See also: Blood and Blood Vessels Noun 1. in Sydney, Australia. Grant recipients are selected by the 12-member Grant Review and Award Committee (GRAC GRAC Global Readiness Assistance Conservation ) comprising senior clinicians and hemophilia researchers from around the world. Dr. Gilbert White
This year, the 26 recipients represent 17 countries worldwide. Since the program's inception in 2002, 76 hemophilia professionals have received grants from Bayer BP totaling nearly $9 million for their work in hemophilia care. Award categories include hemophilia special projects, early career investigators, clinical scholarships, and caregiver education. The BHAP grant recipients utilize the funding to further research and education which supports the next generation of care for individuals with hemophilia. "The Bayer Hemophilia Awards Program supports research and education programs that ultimately will help shape the future of hemophilia care, allowing people living with hemophilia and their families to enjoy a better quality of life through improved treatment options," said Mike Mathews, Vice President of Global Marketing, Bayer Biological Products Division. "The quality of projects funded by BHAP continues to be nothing less than outstanding. We commend these professionals for their dedication to the global hemophilia community and, through BHAP, we are pleased to provide them with monetary support to continue their research and educational efforts." The 2005 recipients, their institutions, and countries are listed below by category:
Hemophilia Special Projects Award Recipients:
---------------------------------------------
Dr. Brian Feldman The Hospital for Sick Toronto, Canada
Children
Dr. Kathelijn Fischer Van Creveldkliniek Utrecht,
The Netherlands
Dr. Robert Flaumenhaft Beth Israel Deaconess Boston, Mass., USA
Medical Center
Dr. Seiji Madoiwa Jichi Medical School Tochigi, Japan
Dr. Jean-Marie Saint-Remy University of Leuven Leuven, Belgium
Campbell Sheen Canterbury Health Christchurch,
Laboratories New Zealand
Early Career Investigator Award Recipients:
-------------------------------------------
Dr. Rosanna Asselta Dept. of Biology and Genetics Milan, Italy
for Medical Sciences
Dr. Rodney Camire The Children's Hospital of Philadelphia,
Philadelphia Pa., USA
Dr. Peter Gross St. Michael's Hospital Toronto, Canada
Dr. Ade Kallas Institute of Cell and Molecular Tartu, Estonia
Biology, Univ. of Tartu
Dr. Christoph Konigs J.W. Goethe University Frankfurt,
Germany
Clinical Scholarship Award Recipients:
--------------------------------------
Dr. Marianna Caramella Angelo Bianchi Bonomi HTC Milan, Italy
Dr. Jennifer Domm New York Weill Cornell New York, N.Y., USA
Center
Dr. Suman Sood Penn Comprehensive Philadelphia, Pa.,
Hemophilia and Thrombosis USA
Dr. Katharina Thom Children's Hospital- Vienna, Austria
University of Vienna
Dr. Yung-Li Yang National Taiwan University Taipei, Taiwan
Hospital
Caregivers Education Award Recipients:
--------------------------------------
Chloe Becca Mountain States Regional Tucson, Ariz., USA
Hemophilia Center
Nooshin Behestipoor Shiraz University of Medical Shiraz, Iran
Sciences
Anna Bottos Ospedale Civile Di Padova Padova, Italy
Maria Correa Hemocentro-State University Campinas, Brazil
of Campinas
Laszlo Csuja Friends of Haemophiliacs Budapest, Hungary
Robyn Devenish National Institute of Public Phnom Penh, Cambodia
Health
Patricia Guillon C.H.U. Caen Caen, France
Andrea Pritchard University of Calgary, Calgary, Canada
Faculty of Nursing
Jing Sun Dept. of Hematology, Nanfang Guangzhou, China
Hospital
Cathy Walker Kingston General Hospital Kingston, Ontario,
Canada
A 2004 Early Career Investigator award recipient, Dr. Vince Jenkins, of the National Centre for Hereditary Coagulation Disorders Coagulation Disorders Definition Coagulation disorders deal with disruption of the body's ability to control blood clotting. The most commonly known coagulation disorder is hemophilia, a condition in which patients bleed for long periods of time before , St. James' Hospital, and Trinity College Trinity College, Ireland: see Dublin, Univ. of. Trinity College Private liberal arts college in Hartford, Conn., founded in 1823. It is historically affiliated with the Episcopal church, though its curriculum is nonsectarian. in Dublin, Ireland, has certainly seen the value of the Bayer Hemophilia Awards Program and encourages other investigators to apply. "With the research grant I received from the Bayer Hemophilia Awards Program, I've been given the opportunity to pursue my specific research interests in hemophilia and design my own research project," said Jenkins. "As one of the best sources of hemophilia research funding, I would encourage any investigator to apply for a Bayer Hemophilia Awards Program grant." Letters of Intent (LOI LOI Letter of Indemnity (international trade and carriage business) LOI Letter Of Intent LOI Loss On Ignition LOI Letter of Inquiry LOI Lack Of Information LOI Lack of Interest LOI Letter of Invitation LOI List Of Items ) for the 2006 Bayer Hemophilia Awards are accepted throughout this year, with Oct. 31, 2005, being the deadline for LOI submissions. For complete information on the Bayer Hemophilia Awards Program, award categories, and submission process, visit the Web site at www.bayer-hemophilia-awards.com. About Hemophilia Approximately 400,000 people around the world have hemophilia. Hemophilia is an inherited bleeding disorder Bleeding disorder Problems in the clotting mechanism of the blood. Mentioned in: Lithotripsy bleeding disorder Coagulopathy, see there characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. The disease is caused by deficient or defective blood coagulation Noun 1. blood coagulation - a process in which liquid blood is changed into a semisolid mass (a blood clot) blood clotting clotting, coagulation, curdling - the process of forming semisolid lumps in a liquid proteins, known as factor VIII factor VIII n. A factor in the clotting of blood, a deficiency of which is associated with hemophilia A. Also called antihemophilic factor, antihemophilic globulin, antihemophilic globulin A, or IX. The most common form of the disease is hemophilia A hemophilia A n. Hemophilia due to deficiency of factor VIII, characterized by prolonged clotting time, decreased formation of thromboplastin, and diminished conversion of prothrombin. , or classic hemophilia classic hemophilia see hemophilia A. , in which the clotting factor clot·ting factor n. Any of various plasma components involved in the clotting of blood, including fibrinogen, prothrombin, thromboplastin, and calcium ion. Also called coagulation factor. VIII is either deficient or defective. Hemophilia B hemophilia B n. A clotting disorder of blood resembling hemophilia A, caused by hereditary deficiency of factor IX. Also called Christmas disease. is characterized by deficient or defective factor IX. About Bayer HealthCare AG Bayer HealthCare AG, a subsidiary of Bayer AG Bayer AG German chemical and pharmaceutical company. Founded in 1863 by Friedrich Bayer (1825–1880), it now operates plants in more than 30 countries. Bayer has originated scores of pharmaceuticals, chemicals, and synthetic materials; it was the first developer and , is one of the world's leading, innovative companies in the healthcare and medical products industry. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics, and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004. Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing, and treating disease. Information about Bayer Biological Products Division can be found at www.bayerbiologicals.com. Forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion